ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: New England Journal of Medicine
Author(s): Massimo Imazio, Antonio Brucato, Roberto Cemin, Stefania Ferrua, Stefano Maggiolini, Federico Beqaraj, Daniela Demarie, Davide Forno, Silvia Ferro, Silvia Maestroni, Riccardo Belli, Rita Trinchero, David H. Spodick, and Yehuda Adler for the ICAP Investigators
240 patients with acute pericarditis randomized to either colchine or placebo in addition to standard NSAIDs.  The colchine group had reduced rate of incessant or recurrent pericarditis.  
Source: Journal of Clinical Oncology
Author(s): Margreet Lüchtenborg, Sharma P. Riaz, Victoria H. Coupland, Eric Lim, Erik Jakobsen, Mark Krasnik, Richard Page, Michael J. Lind, Michael D. Peake, and Henrik Møller
Outcomes for over 12,800 pts operated for lung cancer in England 2004-2008 were analyzed. High volume hospitals operated on patients with more risk factors (advanced age, lower socioeconomic status, more comorbidities), yet achieved better survival, especially in the early postoperative period.
Source: New England Journal of Medicine
Author(s): John W. Eikelboom, Stuart J. Connolly, Martina Brueckmann, Christopher B. Granger, Arie P. Kappetein, Michael J. Mack, Jon Blatchford, Kevin Devenny, Jeffrey Friedman, Kelly Guiver, Ruth Harper, Yasser Khder, Maximilian T. Lobmeyer, Hugo Maas, Jens-Uwe Voigt, Maarten L. Simoons, and Frans Van de Werf, for the RE-ALIGN Investigators
This randomized trial of dabigatran vs warfarin for anticoagulation in patients immediately after or more than 3 mos after MVR or AVR with a mechanical valve was stopped early after enrollment of 252 pts. There were both excess bleeding events and excess thromboembolic events in the dabigatran group, indicating no benefit and increased risk of dabigatran compared to warfarin.
Source: New England Journal of Medicine
Author(s): David S. Wald, Joan K. Morris, Nicholas J. Wald, Alexander J. Chase, Richard J. Edwards, Liam O. Hughes, Colin Berry, and Keith G. Oldroyd, for the PRAMI Investigators
465 pts with acute STEMI who were undergoing urgent PCI were randomized to additional prophylactic PCI of any vessels with significant stenosis or PCI of the target vessel only. The composite outcome was cardiac death + MI + refractory angina. The trial was stopped early because of a incidence of composite outcome of 21 (9 per 100 pts) in the prophylactic PCI group vs 53 (23 per 100 pts) in the control group (HR of 0.35; p<0.001). Similar benefits were seen for each component of the composite outcome.
Source: European Journal of Cardiothoracic Surgery
Author(s): EACTS Clinical Guidelines committee
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and its prevalence is ∼1–2% of the general population, but higher with increasing age and in patients with concomitant heart disease. The Cox-maze III procedure was a groundbreaking development and remains the surgical intervention with the highest cure rate, but due to its technical difficulty alternative techniques have been developed to create the lesions sets. The field is fast moving and there are now multiple energy sources, multiple potential lesion sets and even multiple guidelines addressing the issues surrounding the surgical treatment of AF both for patients undergoing this concomitantly with other cardiac surgical procedures and also as stand-alone procedures either via sternotomy or via videothoracoscopic techniques. The aim of this document is to bring together all major guidelines in this area into one resource for clinicians interested in surgery for AF. Where we felt that guidance was lacking, we also reviewed the evidence and provided summaries in those areas. We conclude that AF surgery is an effective intervention for patients with all types of AF undergoing concomitant cardiac surgery to reduce the incidence of AF, as demonstrated in multiple randomized studies. There is some evidence that this translates into reduced stroke risk, reduced heart failure risk and longer survival. In addition, symptomatic patients with AF may be considered for surgery after failed catheter intervention or even as an alternative to catheter intervention where either catheter ablation is contraindicated or by patient choice.
Source: European Journal of Cardiothoracic Surgery
Author(s): Kiyotaka Imoto, Keiji Uchida, Norihisa Karube, Toru Yasutsune, Tonoki Cho, Kazuo Kimura, Munetaka Masuda, and Satoshi Morita
Seventy-five patients with acute type A aortic dissection with coronary artery dissection were analyzed. Preoperative cardiopulmonary arrest and myocardial ischemia were associated with poor survival outcome whereas early revascularization resulted in a lower frequency of low cardiac output syndrome.
Source: European Journal of Cardiothoracic Surgery
Author(s): Paul P. Urbanski, Husam Hijazi, Witold Dinstak, and Anno Diegeler
Forty-six patients with acute type A aortic dissection underwent valve-sparing root repair with replacement of all pathological sinuses of Valsalva. The actuarial survival rate at 8 years was 85.5 ± 5.6% with no valve-related events and no reoperation on the proximal aorta/aortic valve during the follow-up
Source: European Journal of Cardiothoracic Surgery
Author(s): Moritz Seiffert, Lenard Conradi, Stephan Baldus, Johannes Schirmer, Stefan Blankenberg, Hermann Reichenspurner, Patrick Diemert, and Hendrik Treede
About 3% of 458 TAVI patients required emergent conversion to open surgery with a 30-day mortality of 38.5% in a monocenter analysis. The importance of a interdisciplinary surgical and interventional safety net is emphasized.
Source: YOUTUBE
Author(s): Arie Bitz
A 41 minute presentation on some of the techniques used to address MAC (mitral annular calcification) is followed by an operative video demonstrating several of the techniques. Techniques include mechanical debridement, CUSA debridement, supra-annular MVR, and infra-annular MVR.
Source: Journal of Cardiothoracic and Vascular Anesthesia
Author(s): Joanne Guay
uay J et al. – The study aims to determine major adverse outcomes, including the risk of mediastinal reexploration, death, stroke and myocardial infarction, associated with continuing antiplatelet therapy in patients undergoing surgery with cardiopulmonary bypass. Continuing antiplatelet therapy for patients undergoing surgery with cardiopulmonary bypass (CPB) is associated with a low risk for reexploration. Methods A meta–analysis of parallel randomized, controlled trials published in English. Patients undergoing surgery with cardiopulmonary bypass (CPB). Continuing antiplatelet therapy versus stopping antiplatelet therapy before the surgery. A search was conducted in PubMed, EMBASE, MEDLINE(R), and the Cochrane Central Register of Controlled Trials. Twelve studies were retained for analysis. Results Continuing antiplatelet drugs for CPB increases the rate of reexploration by a standardized mean difference (SMD) 0.22, 95% confidence interval (CI) 0.06, 0.39; I–square 0%; p value 0.01; classical fail–safe number 5. The number needed to harm (NNTH) is 87 (95% CI 390, 44). There was no statistical difference for death at 30days and 1year, myocardial infarction at 30days, and stroke at 30days. Continuing antiplatelet drugs increases blood loss, SMD 0.27 (95% CI 0.09, 0.45), I–square 73.1%; p=0.003.

Pages